Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Clinical trial NCT03233724 · TERMINATED

Trial details

NCT number: NCT03233724
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Lung Cancer Non-Small Cell Lung Cancer Carcinoma, Esophageal Malignant Pleural Mesotheliomas

Start date: 2018-04-11
Primary completion: 2021-10-06
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.